The COVID crisis has had a considerable impact on research across the UK and indeed worldwide. In March 2020 recruitment to both REIMAGINE research studies, at all NHS sites, was halted so to protect patients and the NHS, with several members of the consortium called to assist with the frontline fight against Covid-19. We are continuing to assess the potential impact and knock-on delays to the studies.
After careful planning and risk assessment we are glad to say that recruitment to the Prostate Cancer Risk Study (Work strand 1) and Prostate Cancer Screening study (Work strand 2) is once again open at all previously active sites. Recruitment pathways and research activities have been modified so to ensure this research can continue in a safe and robust manner for both patient and the NHS alike.
We are in the process of preparing videos to describe how the studies have evolved and changes you could expect at the NHS site should you participate. These videos will be available on the website shortly.
As a prostate cancer survivor,
it is a privilege to be able to contribute to a study that has the potential to deliver new methods of testing for prostate cancer that are more reliable, more accurate and less invasive than the current prostate-specific antigen (PSA) test and biopsies. Not all men with prostate cancer are as fortunate as me; I had symptoms that indicated a problem, even though my PSA result was 'normal', but many men have no symptoms at all. We need a test that clinicians and patients can trust.
The ReIMAGINE consortium seeks to change forever the way in which prostate cancer is diagnosed, the manner in which it is classified, the method by which risk is communicated, the utility associated with the diagnosis, the benefit that is derived from intervention and reduce the overall costs of care.
The precise risk-stratification that results from an image-based measurable-disease approach will allow us to determine whether progression in prostate cancer is clonally specified or is a transitional phenomenon.
The risk stratification of prostate cancer that will emerge from ReIMAGINE will permit a departure from today’s one-size-fits-all approach towards an individualised care that matches the very broad risk profile of this ill understood disease.